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Abstract
Background: Dehydroepiandrosterone (DHEA) has been suggested as an immunostimulating steroid
hormone, of which the effects on the development of dendritic cells (DC) are unknown. The effects of
DHEA often oppose those of the other adrenal glucocorticoid, cortisol. Glucocorticoids (GC) are
known to suppress the immune response at different levels and have recently been shown to
modulate the development of DC, thereby influencing the initiation of the immune response.
Variations in the duration of exposure to, and doses of, GC (particularly dexamethasone (DEX))
however, have resulted in conflicting effects on DC development.
Aim: In this study, we describe the effects of a continuous high level of exposure to the adrenal steroid
DHEA (1026 M) on the generation of immature DC from monocytes, as well as the effects of the
opposing steroid DEX on this development.
Results: The continuous presence of DHEA (1026 M) in GM-CSF/IL-4-induced monocyte-derived DC
cultures resulted in immature DC with a morphology and functional capabilities similar to those of
typical immature DC (T cell stimulation, IL-12/IL-10 production), but with a slightly altered
phenotype of increased CD80 and decreased CD43 expression (markers of maturity).
The continuous presence of DEX at a concentration of 1026 M in the monocyte/DC cultures
resulted in the generation of plastic-adherent macrophage-like cells in place of typical immature DC,
with increased CD14 expression, but decreased expression of the typical DC markers CD1a, CD40 and
CD80. These cells were strongly reactive to acid phosphatase, but equally capable of stimulating T cell
proliferation as immature DC. The production of IL-12 by these macrophage-like cells was virtually
shut down, whereas the production of IL-10 was significantly higher than that of control immature
DC.
Conclusion: The continuous presence of a high level of GC during the generation of immature DC from
monocytes can modulate this development away from DC towards a macrophage-like cell. The
combination of a low CD80 expression and a shutdown of IL-12 production suggests the possibility of
DEX-generated cells initiating a Th2-biased response. These effects by DEX on DC development
contrast with those by DHEA, which resulted in a more typical DC although possessing a phenotype
possibly indicating a more mature state of the cell.
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Introduction
Dehydroepiandrosterone (DHEA) is quantitatively the
most abundant adrenal steroid hormone in humans
and other mammals (1, 2). The hormone is uniquely
sulfated (DHEA-S) before entering the plasma, and the
sulfated prohormone is converted to DHEA and its
metabolites (3) in various peripheral tissues. No major
endocrine functions have been ascribed to a direct
action of DHEA-S and DHEA, although the hormones
act as intermediaries in sex steroid synthesis (3). Both
hormones, however, have been proposed as exerting
important restoring effects on age-related processes,
such as fat depot distrubution and neurodegeneration.
These effects also include major stimulation of cells of
the (aging) immune system (4±6). However, these
effects of DHEA have also been disputed (7, 8).
Dendritic cells (DC) are antigen-presenting cells par
excellence, and the only cells capable of stimulating
naõÈve T cells and thus capable of initiating primary
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immune responses (9). A well-accepted method of
generating DC from monocytes is the culture of
monocytes in the presence of the cytokines GM-CSF
and IL-4 for 7 days (10). This procedure yields the so-
called `immature' DC, with a retained capability for
uptake and processing of antigens but with a relatively
low capability to stimulate T cells. A further exposure of
`immature' DC to pro-inflammatory stimuli (e.g. IL-1,
lipopolysaccharide (LPS)) generates mature forms of
the cell with an enhanced capability to stimulate T
cells, but an almost lost capability for antigen uptake
and processing (11).
There are no reports on the effects of DHEA on
dendritic cell development. We previously reported that
the exposure of monocytes to hormones (in particular
to triiodothyronine) stimulated DC development from
monocytes (12, 13). We now have tested and report
here the effects of exposure of monocytes to DHEA,
prior to, and during, their differentiation into immature
DC under the influence of GM-CSF and IL-4.
In biological systems, the effects of DHEA-S and
DHEA are often opposed by the other important
adrenal steroid cortisol (14). The ratio DHEA/cortisol
is abnormal in various pathological conditions charact-
erized by immune dysfunction, such as after thermal
injury, in AIDS, in rheumatoid arthritis and in
tuberculosis (15±19). Although the suppressive effects
of glucocorticoids on T cells, B cells, monocytes and
macrophages have extensively been studied (reviewed
in 20, 21), there is a growing, but still limited number
of reports on the effects of glucocorticoids on the
function and differentiation of DC (22±26). Data in
these reports are inconsistent regarding effects on
marker expression, T cell-stimulatory capacity and
cytokine production. We therefore contrasted our
DHEA experiments with dexamethasone (DEX) and
tested the effect of this hormone on the process of the
transition from monocyte to immature DC also.
Materials and methods
Isolation of monocytes from peripheral blood
Monocytes were isolated from the peripheral blood of
healthy blood donors via well-accepted methods. Hepar-
inized blood diluted with an equal volume of phosphate
buffered saline (PBS) was distributed over Ficoll Isopaque
(density 1.077 g/ml, Pharmacia, Uppsala, Sweden) and
centrifuged for 15 min at 1000 g. Cells were collected
from the interface and washed and then suspended in
RPMI 1640 with 25 mM HEPES and L-glutamine (GIBCO,
Life Technologies, Breda, The Netherlands), supplemented
with 100U/ml penicillin G, 0.1 mg/ml streptomycin (both
Seromed, Biochrom, Berlin, Germany) and 10% FCS (Bio
Whitaker, USA) (hereafter known as RPMI 1640+) added.
This cell suspension was distributed over Percoll (density
1.063 g/ml, Pharmacia, Uppsala, Sweden), then centri-
fuged for 40 min at 400 g. Cells collected from the
interface were washed and suspended in RPMI 1640+.
Monocyte purity was determined by non-specific esterase
staining (NSE) (27). Cell suspensions containing 80% or
more monocytes were frozen following standard proce-
dures and stored in liquid nitrogen, providing a bank for
experiments. Monocytes purified by elutriator centrifuga-
tion were also used (courtesy of CLB, Amsterdam), in
order to confirm results obtained via Ficoll/Percoll
gradient separation.
Culture of DC from peripheral blood
monocytes
DC were obtained via the well-established method first
described by Sallusto and Lanzavecchia (10). Briefly,
monocytes were cultured for 1 week at 37 8C, in 5%
CO2 and 100% humidity at a concentration of 3 
105 cells=ml in RPMI 1640+ with 800 U/ml GM-CSF
and 1000 U/ml IL-4. The cultures were fed every 2
days, by removing 500 ml culture fluid and replacing
this with 1 ml of fresh medium containing cytokines.
In order to test the effects of exposure to DHEA and DEX
on the monocyte-to-DC transition, these hormones
were added at an optimal concentration of 1026 M to
monocytes in RPMI 1640 culture medium (without
FCS) and incubated for 30 min at 37 8C, 5% CO2,
100% humidity after which FCS (10%), GM-CSF
(800 U/ml) and IL-4 (1000 U/ml) were added to the
culture. DHEA and DEX were also fed to the cultures
every 2 days along with fresh medium and cytokines.
All culture medium used was tested and found to be
free of endotoxin. Both hormones were purchased free
from endotoxin contamination.
Flow cytometry and immunocytochemistry
For analysis of marker expression by flow cytometry, all
cell populations were stained by incubating for 10 min
with mouse anti-human FITC- or PE-conjugated
monoclonal antibodies, followed by three washes. The
monoclonal antibodies used were My4 (CD14, Beckman
Coulter, Hialeah, FL, USA), CD1a (Beckman Coulter,
Hialeah, FL, USA), B7.1 (CD80, Becton Dickinson, San
Jose, CA, USA), B7.2 (CD86, PharMingen, Los Angeles,
CA, USA), CD 40 (Serotec, Oxford, UK), CD43
(Biosource, Camarillo, CA, USA) and CD83 (Immuno-
tech, Marseilles, France). Immediately following the
staining, cells were analyzed on a FACScan (Becton
Dickinson, San Jose, CA, USA).
The reactivity of the various monocyte/DC popula-
tions to acid phosphatase was determined using
cytospins prepared on a Cytospin apparatus (Nordic
Immunological Laboratories, The Netherlands) Cyto-
spins were air-dried, then incubated for acid phospha-
tase staining according to Katayama et al. (28), using
naphtol AS-BI phosphate as substrate and hexarotised
pararosanilin as coupling agent (37 8C, 30 min). Slides
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were counterstained with hematoxylin. Preparations
were mounted in DePex mounting medium (Gurr, BDH
Ltd, Poole, UK).
Mixed leukocyte reaction
Allogeneic mixed leukocyte reactions (MLRs) were
performed in order to measure the accessory capability
of the various DC populations generated. Responder T
lymphocytes were obtained from a healthy donor and
isolated following standard procedures with Ficoll-
isopaque, Percoll density gradient centrifugation, and
nylon wool adherence (Leuko-Pak, Fenwall Labora-
tories, IL, USA). Non-adhering cells recovered were
greater than 90% CD3 positive. A total of 1:5  105
responder cells were cultured in 96-well, flat-bottom
microtitre plates (NUNC A/S International, Denmark)
with different numbers of irradiated (2000 rad)
stimulator cells (monocytes or DC) to achieve stimu-
lator-to-T cell ratios of 1:5, 1:10, 1:20 and 1:40. The
culture medium used was RPMI 1640 with 25 mM
HEPES and L-glutamine, supplemented with 100 U/ml
penicillin G, 0.1 mg/ml streptomycin and 10% human
A+ serum, in a total volume of 200 ml per well. The
controls used were monocytes or DC alone, and
lymphocytes in the presence of 10±50 mg/ml phyto-
hemagglutinin (PHA) (Wellcome Diagnostics, Zeist,
The Netherlands). Cultures were performed in tripli-
cate. On day 5, thymidine incorporation was assayed by
adding 0.5 mCi [3H]-thymidine to each well. Cells were
harvested 16 h later and the radioactivity counted on
an LKB 1205 Betaplate liquid scintillation counter
(Wallac, Turku, Finland).
IL-12/IL-10 production
The DC were placed in 24-well plates (NUNC) at a
concentration of 5  105 cells=ml and cultured for 24 h
in RPMI+ containing ultraglutamine (2 mM, BioWhi-
taker), penicillin/streptomycin (100 U/ml, 100 mg/ml,
BioWhitaker) and serum free medium supplement
(Pepro Tech, Rocky Hill, NJ, USA). To stimulate IL-10
production, the culture fluid contained Staphylococcus
aureus cowan 1 strain (SAC) (1:5000, Calbiochem, La
Jolla, CA, USA). The IL-12 production was stimulated
by SAC (1:5000) and g-IFN (1000 U/ml, Biomedical
Primate Research Centre, Rijswijk, The Netherlands).
The production was measured by ELISA as indicated by
the manufacturer (for IL-10, ELISA Pelikine, CLB,
Amsterdam, The Netherlands; IL-12, Eli-pair, Diaclone,
BesancËon, France).
Results
DHEA and DEX influence the phenotype of DC
in culture
Dose±response curves were carried out to determine
the optimal concentration of DHEA to add to the
monocytes in culture. On the basis of our previous
experience using various hormones to generate veiled
cells (12, 13), the optimal concentration was deter-
mined to be that which resulted in the greatest number
of cells displaying a veiled morphology. The optimal
concentration for DHEA was found to be 1026 M. In
the case of DEX, we had previously carried out dose±
response curves and have shown that although
concentrations of 1029 M were already effective, a
concentration of 1026 M added to DC obtained from
bronchial alveolar lavage was optimal for obtaining a
decreased function as well as a decrease in co-
stimulatory molecule expression (29). We have there-
fore used 1026 M DHEA and 1026 M DEX in our
subsequent experiments.
The addition of DHEA and DEX to the cultures
resulted in the generation of DC with significantly
different phenotypes than those generated with cyto-
kines alone (Fig. 1), while not affecting cell viability or
cell survival, as determined by cell recovery numbers
and trypan blue exclusion.
Adding DHEA to the cultures resulted in a DC
population with a marked upregulation of the co-
stimulatory molecule CD 80 (45 ^ 9% vs 22 ^ 8%
positive cells in the control culture, P  0:05: This was
contrasted by a sharp downregulation of CD80 when DEX
was added (1 ^ 0% vs. 22 ^ 8% positive cells in the
control culture, P  0:05). Moreover, in the presence of
DEX the morphology of the cells had changed, appearing
as largely adherent macrophage-like cells with blunted
cytoplasmic processes. The expression of the co-stimul-
atory molecule CD86 remained constant, regardless of
exposure to either DHEA or DEX.
Both hormones decreased the expression of the anti-
adhesion molecule CD43 (a marker of immature DC,
see Discussion) from 49 ^ 8% positive cells in the
control culture to 27 ^ 2% positive cells in the DHEA
culture P  0:04 and 27 ^ 4% positive cells in the
DEX culture P  0:04. Whereas DHEA had no effect
on CD40 expression, the addition of DEX to the culture
significantly downregulated its expression (96 ^ 2%
positive cells in the control culture vs 52 ^ 7% positive
cells in the dexamethasone culture, P  0:04). Both
CD43 and CD40 play a role in the further maturation
of immature DCs by inducing homotypic interactions
(see Discussion) or when ligated by CD40 ligand on T
cells respectively.
The expression of CD1a was also downregulated by
DEX from 49 ^ 18% positive cells in the control culture
to 1 ^ 1% positive cells in the DEX culture (Fig. 1). The
presence of DHEA in the culture also resulted in a slight
decrease in CD1a expression, from 49 ^ 18% positive
cells in the control culture to 32 ^ 0% in the DHEA
culture (Fig. 1).
The expression of the mature DC marker CD83 was
extremely low in all cultures, underscoring the
immature status of all DC populations under study.
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Figure 1 The CD80, CD86, CD43, CD40, CD1a, CD83 and CD14 expression as determined by FACS analysis of control monocyte-
derived DC and DC derived from monocytes in the continuous presence of 1026 M DHEA (DHEA DC) or 1026 M dexamethasone (DEX
DC). (a) Means (^ S.D.) of percentage positive cells are given; only large cells were included. P values are as indicated, n  at least five
separate experiments. (b) Overlapping histogram profiles of the expression of each marker in a representative experiment. Control DC are
represented by a fine line, DHEA DC are represented by a dotted line and DEX DC are represented by a thick line.
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As expected, most dendritic cells from the control
cultures were CD14 negative. A significant increase in
CD14 marker expression was seen in cells from cultures
containing DEX (74 ^ 8% positive cells vs 12 ^ 11%
positive cells in control cultures, P  0:04). Cells from
the cultures containing DHEA did not express CD14 in
significantly higher amounts than those from the
control cultures. Moreover, staining of cytospin pre-
parations revealed that cells from the DEX cultures
were strongly reactive with acid phosphatase in
contrast to those from the DHEA- and control cultures
which reacted weakly with acid phosphatase.
Thus, in summary, the addition of DHEA enforced
the DC-character of the cells with a high CD80 and low
CD43 expression, whereas DEX in fact changed the
phenotype of the cells into more macrophage-like
CD14+ cells, lacking CD1a CD80 and CD40 expression.
Functional differences induced by DHEA and
DEX in DC culture
Dendritic cells were co-cultured with allogeneic T cells in
mixed leukocyte reactions in order to measure their
capacity for stimulating T cell proliferation (Fig. 2).
Dendritic cells generated under the influence of DHEA
stimulated T cell proliferation as successfully as the
control immature dendritic cells. Dendritic/macro-
phage-like cells generated under the influence of DEX
were also able to stimulate T cell proliferation at a
comparable level to the control dendritic cells; however, a
non-significant difference at a stimulator-to-T cell ratio
of 1:10 may suggest that these DC may be slightly inferior
at higher ratios. As the number of mixed leukocyte
reactions performed was limited n  3; further experi-
mentation should elucidate whether or not DC generated
in the presence of DEX are truly as capable of stimulating
T cell proliferation (at all ratios) as control immature DC.
The ability of all DC populations generated to stimulate T
cell proliferation at a stimulator-to-T cell ratio of 1:40
was comparable to the control PHA response. At a
stimulator-to-T cell ratio of 1:10, this response was three
times that of the PHA control.
Dendritic cells generated in the presence of DHEA
produced IL-10 and IL-12 in not significantly higher
amounts than the control DC (Fig. 3). Dendritic/
macrophage-like cells generated under the influence
of DEX, however, produced significantly more IL-10
than the control DC (1825 ^ 503 pg=ml vs. 323 ^
114 pg=ml respectively; mean ^ S.E.M.; P  0:05) and
virtually shut down their production of IL-12, in
contrast to the control DC (0 ^ 0 pg=ml vs. 831 ^
490 pg=ml respectively; mean ^ S.E.M.; P  0:05).
Discussion
Glucocorticoids are well known for their potent immu-
nosuppressive effects when given in pharmacological
doses. There are numerous reports of such suppressive
effects on T cells, B cells and macrophages (reviewed in
20, 21). With regard to DC, various studies indicate that
exposure to glucocorticoids decreases the function and
number of DC in vivo (30±32). Literature on the effects
of glucocorticoids on the in vitro generation of
immature and mature DC from their precursors, or
on the T cell stimulatory capability of glucocorticoid-
exposed DC is increasing (22±26). These reports until
now collectively show that the function of DC and the
generation of immature and mature DC from mono-
cytes is negatively influenced by the in vitro addition of
glucocorticoids. Nevertheless, the precise data on the
effects of glucocorticoids on DC marker expression,
function and maturation are inconsistent. The reasons
for the differences among observations are largely
unclear, yet it is likely that they include the different
maturation states of the DC used and the different
exposure times to different doses of glucocorticoids in
these experiments. When Van den Heuvel et al. (24)
exposed GM-CSF/IL-4-cultured human monocytes not
continuously, as in this report, but only for brief periods
to DEX (early or late in the culture period), a population
of immature DC was generated with a decreased
accessory capability. This difference in function
occurred in these experiments in the absence of
changes in the expression of co-stimulatory molecules.
Piemonte et al. (23) exposed GM-CSF/IL-4-cultured
human monocytes not for brief periods, but continu-
ously to DEX; they however used a lower concentration
of DEX than in this report (i.e. 1028 M). These authors
Figure 2 The T cell stimulatory capacity in allo-MLR of the various
DC populations studied. Mean c.p.m.  1000 (^ S.D.) are given for
various DC:T cell ratios (1:40; 1:20; 1:10).
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again induced cells with a DC morphology, but with a
lower expression of CD86, CD40 and CD1a, a higher
expression of MHC-class II, adhesion molecules and
CD14, as well as an enhanced antigen uptake via the
mannose receptor. The cells again had a poor T cell
stimulatory capability. Vieira et al. (22) reported that
when they similarly produced immature DC in rela-
tively low concentrations of glucocorticoids, they were
poor in the production of IL-12 p-70, tumor necrosis
factor (TNF)-a and IL-6 (when stimulated with LPS);
however, these authors found a normal expression of
CD80 and CD86, a normal antigen uptake, and a
normal T cell stimulatory capability of such cells.
Vanderheyde et al. (25) used already-generated
immature monocyte-derived DC and exposed these
cells to methyl-prednisolone GM-CSF/IL-4 (100 mg/ml)
for 24 h. The cells enhanced their antigen uptake and
downregulated their basal expression of CD86 and their
T cell stimulation potential. The treatment also
prevented LPS-induced maturation, but had limited
effects on CD40-induced further maturation. A recent
study by Matasic et al. (26) also exposed already-
generated immature monocyte-derived DC to DEX. The
authors confirmed that 500 nM DEX prevented further
DC maturation. In fact, the treatment redirected the
differentiation of the DC to a more monocyte-macro-
phage type of cell (high CD14, high CD68, low T cell
stimulatory potential).
Here we describe that a continuous exposure of
monocytes to a high concentration of DEX (1026 M)
completely abolished the generation of cells with an
immature phenotype and morphology of DC from
monocytes, and induced a set of largely plastic-adherent
macrophage-like cells, expressing increased levels of
CD14 and decreased levels of `typical' DC markers such
as CD1a, CD40 and CD80. These cells were also
strongly reactive to acid phosphatase, yet had a T cell
stimulating potential in allo-MLR similar to that of
`immature' DC. They did not, however, produce IL-12
but did produce high quantities of IL-10. The CD80
expression of these macrophage-like cells was very low.
In combination with the virtual shutdown of IL-12
production, this suggests that these cells could possibly
initiate a Th2-biased response. In vivo studies also
indicate that exposure to glucocorticoids is able to
increase the numbers of (suppressor) macrophages (31,
33). Our data are in line with such an effect, suggesting
that the Mé/DC balance is affected by glucocorticoids,
which skew this dynamic equilibrium in a macrophage
direction when monocytes are continuously exposed to
DEX during DC maturation. During this exposure, DEX
passively diffuses through the cell membrane, binding
to the resting glucocorticoid receptor (GR). The
resulting activation of the GR causes it to bind to
glucocoticoid-responsive elements (GRE) in the
nucleus, influencing gene transcription.
Taken together, a picture is emerging in which
glucocorticoids have multiple effects on DC biology.
Besides the previously reported negative effects on DC
trafficking (34), function (25, 30) and increases in
apoptosis of DC (35), glucocorticoids also have shown
in many studies variable `suppressive' and `altering'
effects on the maturation of DC. This probably depends
on the dose and time schedule of exposure, and the
maturation state of the target DC population.
Serum DHEA-S levels show a steady decline with
aging, coinciding with the decline in immune function
in old age (`immunosenescence'). When aged indivi-
duals, being it experimental animals (36±38) or
humans (39) are administered DHEA, their immune
function has been claimed to be restored; they become
more resistant to infections, their secretion of T cell
cytokines (e.g. IL-2) is enhanced, whereas monocyte
numbers are increased. Hence, DHEA is viewed by
some as an immunostimulating hormone. However,
data are also accumulating that such effects of DHEA
are minimal or absent (7, 8).
Our data on the effects of DHEA on DC development
are in line with the view that DHEA has a modest
potentiating effect on immune function. DHEA syner-
gized in our hands with GM-CSF and IL-4 to generate
DC with a higher expression of the co-stimulating
Figure 3 The IL-10 and IL-12 production of control DC, DHEA DC and DEX DC (see Fig. 1 for abbreviations). Means (^ S.D.) of production
(pg/ml/106 cells) are given. P values are as indicated, n  at least five separate experiments.
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molecule CD80 (whereas the expression of CD86
remained equal to that of the control immature DC)
and a lower expression of CD43. The sialoglycoprotein
CD43 (sialophorin/leukosialin) is a negatively-charged
anti-adhesion molecule. When human DC are treated
with an antibody to CD43, their clustering capability is
enhanced and their phenotypic and functional matura-
tion is mediated (40, 41). Thus, the downregulation of
CD 43 expression by DHEA-induced DC reported here
may indicate a somewhat greater level of maturation
than that of the control DC, which would be in
accordance with the higher CD80 expression of these
cells. However, CD83 expression was still low after DHEA
exposure. An argument against their higher state of
maturation is that the DC generated in the continuous
presence of DHEA produced IL-10 and IL-12 in similar
amounts to the control DC. Their T cell stimulatory
capacity was, however, somewhat higher, although this
was not statistically significant. Despite this seeming lack
of significant functional differences, the phenotypic
profile of the DHEA-induced DC (high CD80 expression)
could signal the potential of these DC to direct the
development of naõÈve Th cells toward a Th1 phenotype
(42). DHEA would then be the first hormone known to
possess this capability, which until now has only been
demonstrated by pro-inflammatory cytokines such as
IL-1 and TNF, and substances like LPS (43).
In saying so, we must be aware that it is still a matter
of debate whether immune cells (or any other cells)
possess specific receptors for DHEA. The effects of DHEA
might not be exerted via DHEA-specific receptors, but
rather via receptors for active androgenic metabolites of
DHEA-S and DHEA generated in immune cells (44).
Specifically leukocytes, including macrophages, possess
the sulphatases and other enzymes important in this
conversion (45, 46).
In conclusion, the data reported here show that the
adrenal hormones DHEA and glucocorticoids both have
effects on monocyte-to-immature DC maturation,
though in a largely opposite manner. The DC matura-
tion data as presented here are suggestive of DHEA
inducing somewhat more mature DC with a possible
Th1-skewing potential, whereas glucocorticoids induce
macrophage-like APC with a possible Th2-skewing
potential. Similar opposing effects of DHEA and cortisol
on the Th1-Th2 balance in vivo have been suggested
(47, 48) and refuted (49, 50) before.
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